Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Net Margin (2024 - 2025)

Prime Medicine's Net Margin history spans 2 years, with the latest figure at 5498.69% for Q4 2025.

  • For Q4 2025, Net Margin fell 356209.0% year-over-year to 5498.69%; the TTM value through Dec 2025 reached 4342.44%, up 222417.0%, while the annual FY2025 figure was 4342.44%, 222417.0% up from the prior year.
  • Net Margin reached 5498.69% in Q4 2025 per PRME's latest filing, down from 4129.14% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 1936.6% in Q4 2024 to a low of 25128.23% in Q3 2024.